US Digestive Health Launches the Largest Installation of Artificial Intelligence (AI) Systems for Colorectal Cancer Screening in the United States The GI Genius™ intelligent endoscopy module shows 50% reduction in missed colorectal polyps with AI technology versus standard colonoscopy
Exton, PA
|
July 06, 2022 08:03 AM Eastern Daylight Time
US Digestive Health (“USDH”), a network of top-rated gastrointestinal (GI) practices, today announced that it is now offering patients AI-assisted colonoscopy screenings with the country’s largest installation of GI Genius™ intelligent endoscopy modules.
In the U.S., colorectal cancer is the third most common form of diagnosed cancer and the second deadliest, with almost 150,000 new cases every year[1]. However, it’s also one of the most treatable cancers, with a 90% survival rate when it is detected and treated early.
Colonoscopy has long been considered the gold standard for detecting polyps that can eventually lead to colorectal cancer. Now, patients at USDH have the strength of an AI-assisted option for screening with GI GeniusTM — the first and only FDA-cleared, commercially available device that employs AI to help physicians detect polyps.
US Digestive Health’s installation of GI GeniusTM is the largest in the world and the first in Pennsylvania. The launch will give patients throughout southeastern, southwestern and central Pennsylvania wide-ranging access to the innovative technology and its enhanced capability.
“GI GeniusTM is a major breakthrough in colorectal cancer screening. In real time, it can help physicians identify hard-to-detect and potentially cancerous polyps,” said Dr. Dale Whitebloom, US Digestive Health’s Chief Medical Officer. “We begin our screening colonoscopies at age 45, which is the most up-to-date recommendation by the U.S. Preventive Services Task Force and American Cancer Society. Adding GI GeniusTM gives us yet another tool to help protect our patients from the scourge of cancer.”
The GI GeniusTM module uses advanced AI software to highlight suspicious areas with a visual marker in real time — serving as the gastroenterologist’s vigilant second observer with a sensitivity rate per lesion of 100%[2]. A study published on March 15 in Gastroenterology, the official medical journal of the American Gastroenterological Society, found that the use of GI GeniusTM in conjunction with a colonoscopy can decrease polyp miss rates by nearly 50%, while other studies have shown that AI-assisted colonoscopy can increase detection rates by up to 14%[3],[4].
Jerry Tillinger, CEO of US Digestive Health, said, “Our mission is to prevent colorectal cancer, and AI-assisted colonoscopy is an incredible advancement in protecting the people of Pennsylvania from this terrible disease. We’re proud to collaborate with Medtronic, as well as our endoscopy partners, AMSURG and PE GI Solutions, to roll out the largest installation of GI GeniusTM not only in the United States but also in the world. As a result, US Digestive Health patients now have access to GI GeniusTM-assisted colonoscopies.”
US Digestive Health was formed in 2019 by Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector, in partnership with member practice partner physicians.
For more information or to schedule a GI GeniusTM-enabled colonoscopy, please visit https://usdigestivehealth.com/.
______________________________________________________________________________________
[1] Cancer.Net. Colorectal Cancer: Statistics. January 2020. Available at: https://www.cancer.net/cancer-types/colorectal-cancer/statistics. Accessed January 22, 2021.
[2] Sensitivity calculated as true positive frame rate. GI Genius™ intelligent endoscopy module [instructions for use]. Mansfield, MA: Medtronic; 2021.
[3] Hassan C, et al. New artificial intelligence system: first validation study versus experienced endoscopists for colorectal polyp detection. Gut. 2020;69(5):799-800
[4] Repici A, Badalamenti M, Maselli R, et al. Efficacy of real-time computer-aided detection of colorectal neoplasia in a randomized trial. Gastroenterology. 2020; 159:512–520.e7.
About US Digestive Health
US Digestive Health oversees a network of over 150 gastroenterology providers and has 26 locations, 15affiliated ambulatory surgery centers, and more than 800 total employees in Pennsylvania. They are at the forefront of the rapidly advancing science of digestive health, bringing new insight into the care, treatment, and prevention of digestive health disorders.
The practices that have joined the US Digestive Health network are: Digestive Disease Associates of Berks and Chester Counties; Main Line Gastroenterology Associates of Chester, Delaware, and Montgomery Counties; Regional Gastroenterology of Lancaster County; Carlisle Digestive Disease Associates of Cumberland County; West Chester Gastrointestinal Group of Chester County; Hillmont G.I. of Montgomery County; The Center for GI Health of Bucks and Montgomery Counties; and Gastrointestinal Specialists of Philadelphia, Montgomery, and Bucks Counties.
About Amulet Capital Partners, LP
Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. For additional information, please visit www.amuletcapital.com.
INDICATIONS
GI Genius™ intelligent endoscopy module is a computer-assisted reading tool designed to aid endoscopists in detecting colonic mucosal lesions (such as polyps and adenomas) in real time during standard white light endoscopy examinations of patients undergoing screening and surveillance endoscopic mucosal evaluations. The GI Genius™ computer-assisted detection device is limited for use with standard white-light endoscopy imaging only. This device is not intended to replace clinical decision-making.
###
Contact Details
LevLane
Lauren Stralo
+1 484-747-9692
Company Website
